title: Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.
abstract: The inactivation of p53 and PTEN tumor suppressor genes is a common genetic event in lung cancer. However, data on the effect of the joint inactivation of tumor-suppressor genes in non-small cell lung carcinoma (NSCLC) are lacking. The purpose of this study was to investigate the alterations in PTEN and p53 genes, as well as to evaluate their mutual role in NSCLC pathogenesis and their impact on survival rate. To that end, polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP), sequencing, methylation-specific PCR, and fragment analysis were used. The results obtained were correlated with clinicopathologic parameters, the level of genomic instability, and patient survival. Overall, 13% of specimens had aberrant p53 only, 13% had inactive PTEN only, and 50% of samples had both genes altered. Correlation analyses showed that the mutual inactivation of p53 and PTEN was a frequent event that was associated significantly with the increased level of genomic instability and lymph node invasion implying their synergistic effect in promoting metastatic phenotype of this kind of cancer. In addition, our results revealed a significant association of joint alterations of these genes with dramatically shortened survival indicating that aberrant p53 and PTEN could be used as an adverse prognostic factor for NSCLC patients' outcome. Our findings established the relevance of the combinatorial inactivation of p53 and PTEN in NSCLC progression and identified a subgroup of patients with a particularly aggressive disease.
authors.affiliation: Department of Neurobiology University of Belgrade, Institute for Biological Research, Republic of Serbia.
authors.forename: Tijana
authors.initials: T
authors.lastname: Andjelkovic
authors.forename: Jasna
authors.initials: J
authors.lastname: Bankovic
authors.forename: Jelena
authors.initials: J
authors.lastname: Stojsic
authors.forename: Vedrana
authors.initials: V
authors.lastname: Milinkovic
authors.forename: Ana
authors.initials: A
authors.lastname: Podolski-Renic
authors.forename: Sabera
authors.initials: S
authors.lastname: Ruzdijic
authors.forename: Nikola
authors.initials: N
authors.lastname: Tanic
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D005091:Exons / Q000235:genetics; D005260:Female; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D016158:Genes, p53; D006801:Humans; D019656:Loss of Heterozygosity; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D009361:Neoplasm Invasiveness / Q000235:genetics; D009367:Neoplasm Staging; D051059:PTEN Phosphohydrolase / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods; D018807:Polymorphism, Single-Stranded Conformational; D015996:Survival Rate
chemical_list: D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human